β2-agonist eutomers: A rational option for the treatment of asthma?

American Journal of Respiratory Medicine

Volumn 1, Issue 5, 2002, Pages 305-311

  Boulton, David W ^a   Fawcett, J Paul ^b  

^a BRISTOL MYERS SQUIBB   (United States)

^b UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; FENOTEROL; FORMOTEROL; IBUPROFEN; ISOPRENALINE; LEVALBUTEROL; LEVODOPA; LONG ACTING DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; ROPIVACAINE; SALBUTAMOL; SALBUTAMOL SULFATE; SALMETEROL; TERBUTALINE; ANTIASTHMATIC AGENT; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR STIMULATING AGENT;

ASTHMA; BRONCHODILATING ACTIVITY; BRONCHUS REACTIVITY; CHIRALITY; CLINICAL TRIAL; DISEASE CONTROL; DRUG EFFICACY; DRUG FORMULATION; DRUG MARKETING; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; EDITORIAL; EVIDENCE BASED MEDICINE; HEART ARRHYTHMIA; HUMAN; IN VIVO STUDY; LIVER TOXICITY; LUNG DISEASE; LUNG FUNCTION; MORTALITY; NONHUMAN; PRIORITY JOURNAL; RACEMIC MIXTURE; SENSITIVITY ANALYSIS; STEREOISOMERISM; TACHYPHYLAXIS; ANIMAL; ARTICLE; CHEMISTRY; DRUG POTENTIATION; IN VITRO STUDY; STRUCTURE ACTIVITY RELATION;

ADRENERGIC BETA-AGONISTS; ALBUTEROL; ANIMALS; ANTI-ASTHMATIC AGENTS; ASTHMA; CLINICAL TRIALS; HUMANS; RECEPTORS, ADRENERGIC, BETA-2; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0042858121     PISSN: 11756365     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03256624     Document Type: Editorial

References (69)

1. Brittain RT, Farmer JB, Marshall RJ. Some observations on the β-adrenoceptor agonist properties of the isomers of salbutamol. Br J Pharmacol 1973; 48: 144-7
2. Patil PN, Millter DD, Trendelenberg U. Molecular geometry and adrenergic drug activity. Pharmacol Rev 1975; 26: 323-92
3. Ariëns EJ. Stereochemistry, a basis for sophisticated nonsense in pharmacokinetics and clinical pharmacology. Eur J Clin Pharmacol 1984; 26: 663-8
4. Cotzias GC, Papavasiliow PS, Gellene R. Modification of Parkinsonism: chronic treatment with L-dopa. N Engl J Med 1969; 280: 337-45
5. Owen MD, Dean LS. Ropivacaine. Expert Opin Pharmacother 2000; 1: 325-36
6. Scott AK. Stereoisomers and drug toxicity. Drug Saf 1993; 8: 149-59
7. Conolly ME, Davies DS, Dollery CT, et al. Resistance to β-adrenoceptor stimulants (a possible explanation for the rise in asthma deaths). Br J Pharmacol 1971; 43: 389-402
8. Speizer FE, Doll R, Heaf P, et al. Investigation into use of drugs preceding death from asthma. BMJ 1968; 1: 339-43
9. Stolley P, Schinnar R. Association between asthma mortality and isoproterenol aerosols: a review. Prev Med 1978; 7: 519-38
10. Crane J, Flatt A, Jackson R, et al. Prescribed fenoterol and death from asthma in New Zealand, 1981-1983: case-control study. Lancet 1989; 8644: 917-22
11. Pearce N, Granger J, Atkinson M, et al. Case control study of prescribed fenoterol and death from asthma in New Zealand, 1977-81. Thorax 1990; 45: 170-5
12. Spitzer WO, Suissa S, Ernst P, et al. The use of beta-agonists and the risk of death or near death from asthma. N Engl J Med 1992; 326: 501-6
13. Suissa S, Ernst P, Boivin JF, et al. A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists. Am J Respir Crit Care Med 1994; 149: 604-10
14. Barrett TE, Strom BL. Inhaled beta-adrenergic receptor agonists in asthma: more harm than good? Am J Respir Crit Care Med 1995; 151: 574-7
15. McFadden ER. Perspectives in β2-agonist therapy: Vox clamantis in deserto vel lux in tenebris? J Allergy Clin Immunol 1995; 9: 641-51
16. Sears MR, Taylor DR. Regular beta-agonist therapy: the quality of the evidence [letter]. Eur Respir J 1992; 5: 896-7
17. Pearlman DS, Chervinsky P, LaForce C, et al. A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma. N Engl J Med 1992; 327: 1420-5
18. Taylor DR, Town GI, Herbison GP, et al. Asthma control during long-term treatment with regular inhaled salbutamol and salmeterol. Thorax 1998; 53: 744-52
19. Pauwels RA, Lofdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997; 337: 1405-11
20. Perrin-Fayolle M. Salbutamol in the treatment of asthma [letter]. Lancet 1995; 346: 1101
21. Perrin-Fayolle M, Blum PS, Morley J, et al. Differential responses of asthmatic airways to enantiomers of albuterol: implications for clinical treatment of asthma. Clin Rev Allergy Immunol 1996; 14: 139-47
22. Cockcroft DW, Swystun VA. Effect of single doses of S-salbutamol, R-salbutamol, racemic salbutamol, and placebo on the airway response to methacholine. Thorax 1997; 52: 845-8
23. Lötvall J, Palmqvist M, Arvidsson P, et al. The therapeutic ratio of R-albuterol is comparable with that of RS-albuterol in asthmatic patients. J Allergy Clin Immunol 2001; 108: 726-31
24. Ramsay CM, Cowan J, Flannery E, et al. Bronchoprotective and bronchodilator effects of single doses of (S)-salbutamol, (R)-salbutamol and racemic salbutamol in patients with bronchial asthma. Eur J Clin Pharmacol 1999; 55: 353-9
25. Cockcroft DW, Davis BE, Swystun VA, et al. Tolerance to the bronchoprotective effect of beta2-agonists: comparison of the enantiomers of salbutamol with racemic salbutamol and placebo. J Allergy Clin Immunol 1999; 103: 1049-53
26. Sanjar S, Kristersson A, Mazzoni L, et al. Increased airway reactivity in the guinea-pig follows exposure to intravenous isoprenaline. J Physiol 1990; 425: 43-54
27. Morley J, Chapman ID, Foster A, et al. Effects of (+) and racemic salbutamol on airway responses in the guinea-pig. Br J Pharmacol 1991; 104: 295P
28. Chapman I, Mazzoni L, Morley J. An anomalous effect of salbutamol in sensitised guinea-pigs [abstract]. Br J Pharmacol 1990; 99: 66P
29. Galland BC, Blackman JG. Enhancement of airway reactivity to histamine by isoprenaline and related β-adrenoceptor agonists in the guinea-pig. Br J Pharmacol 1993; 108: 1016-23
30. Costello RW, Jacoby DB, Fryer AD. Pulmonary neuronal M2 muscarinic receptor function in asthma and animal models of hyperreactivity. Thorax 1998; 53: 613-6
31. Trofast J, Osterberg K, Kallstrom BL, et al. Steric aspects of agonism and antagonism at beta-adrenoceptors: synthesis of and pharmacological experiments with the enantiomers of formoterol and their diastereomers. Chirality 1991; 3: 443-50
32. Schmidt D, Kallstrom BL, Waldeck B, et al. The effect of the enantiomers of formoterol on inherent and induced tone in guinea-pig trachea and human bronchus. Naunyn Schmiedebergs Arch Pharmacol 2000; 361: 405-9
33. Johansson F, Rydberg I, Aberg G, et al. Effects of albuterol enantiomers on in vitro bronchial reactivity. Clin Rev Allergy Immunol 1996; 14: 57-64
34. Templeton AG, Chapman ID, Chilvers ER, et al. Effects of S-salbutamol on human isolated bronchus. Pulm Pharmacol Ther 1998; 11: 1-6
35. Kallstrom BL, Sjoberg J, Waldeck B. Steric aspects of formoterol and terbutaline: is there an adverse effect of the distomer on airway smooth muscle function? Chirality 1996; 8: 567-73
36. Mitra S, Ugur M, Ugur O, et al. (S)-Albuterol increases intracellular free calcium by muscarinic receptor activation and a phospholipase C-dependent mechanism in airway smooth muscle. Mol Pharmacol 1998; 53: 347-54
37. Cho SH, Hartleroad JY, Oh CK. (S)-Albuterol increases the production of histamine and IL-4 in mast cells. Int Arch Allergy Immunol 2001; 124: 478-84
38. Lipworth BJ, Struthers AD, McDevitt DG. Tachyphylaxis to systemic but not to airway responses during prolonged therapy with high dose inhaled salbutamol in asthmatics. Am Rev Respir Dis 1989; 140: 586-92
39. Hancox RJ, Aldridge RE, Cowan JO, et al. Tolerance to beta-agonists during acute bronchoconstriction. Eur Respir J 1999; 14: 283-7
40. Hawkins CJ, Klease GT. Relative potency of (-)- and (±)-salbutamol on guinea pig tracheal tissue. J Med Chem 1973; 16: 856-7
41. Hartley D, Middlemiss D. Absolute configuration of the optical isomers of salbutamol. J Med Chem 1971; 14: 995-6
42. Gumbhir-Shah K, Kellerman DJ, DeGraw S, et al. Pharmacokinetics and pharmacodynamics of cumulative single doses of inhaled salbutamol enantiomers in asthmatic subjects. Pulm Pharmacol Ther 1999; 12: 353-62
43. Nelson HS, Bensch G, Pleskow WW, et al. Improved bronchodilation with levalbuterol compared with racemic albuterol in patients with asthma. J Allergy Clin Immunol 1998; 102: 943-52
44. Gawchik SM, Saccar CL, Noonan M, et al. The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients. J Allergy Clin Immunol 1999; 103: 615-21
45. Handley DA, Tinkelman D, Noonan M, et al. Dose-response evaluation of levalbuterol versus racemic albuterol in patients with asthma. J Asthma 2000; 37: 319-27
46. Black P. Levosalbutamol. Biodrugs 1999; 11: 439-40
47. Ahrens R, Weinberger M. Levalbuterol and racemic albuterol: are there therapeutic differences? J Allergy Clin Immunol 2001; 108: 681-4
48. Busse WW, Greos L, Vaickus L. Lower doses of Xenoprex are as effective as racemic albuterol in the prevention of exercise-induced asthma (EIB) [abstract]. J Allergy Clin Immunol 1999; 103: S136
49. Israel E, Hong C, Claus R, et al. Levalbuterol is effective in the prevention of cold air induced bronchospasm and does not induce tachyphylaxis in the degree of bronchoprotection [abstract]. J Allergy Clin Immunol 2000; 105: S22
50. Boulton DW, Fawcett JP. Pharmacokinetics and pharmacodynamics of single oral doses of albuterol and its enantiomers in humans. Clin Pharmacol Ther 1997; 62: 138-44
51. Borgström L, Nyberg L, Jonsson S, et al. Pharmacokinetic evaluation in man of terbutaline given as separate enantiomers and as the racemate. Br J Clin Pharmacol 1989; 27: 49-56
52. Borgström L, Kennedy BM, Nilsson B, et al. Relative duodenal absorption of the two enantiomers of terbutaline after duodenal administration. Eur J Clin Pharmacol 1990; 38: 621-3
53. Boulton DW, Fawcett JP. Enantioselective disposition of albuterol in humans. Clin Rev Allergy Immunol 1996; 14: 115-38
54. Fawcett JP, Boulton DW. Enantioselective disposition of β2-agonists in humans. In: Costello JF, editor. Sympathomimetic enantiomers in the treatment of asthma. Carnforth: The Parthenon Publishing Group Inc, 1997: 101-122
55. Gumbhir-Shah K, Kellerman DJ, DeGraw S, et al. Pharmacokinetics and pharmacodynamic characteristics and safety of inhaled albuterol enantiomers in healthy volunteers. J Clin Pharmacol 1998; 38: 1096-106
56. Lecaillon JB, Kaiser G, Palmisano M, et al. Pharmacokinetics and tolerability of formoterol in healthy volunteers after a single high dose of Foradil dry powder inhalation via aerolizer. Eur J Clin Pharmacol 1999; 55: 131-8
57. Boulton DW, Fawcett JP. The pharmacokinetics of levosalbutamol: what are the clinical implications? Clin Pharmacokinet 2001; 40: 23-40
58. Ward JK, Dow J, Dallow N, et al. Enantiomeric disposition of inhaled, intravenous and oral racemic-salbutamol in man: no evidence of enantioselective lung metabolism. Br J Clin Pharmacol 2000; 49: 15-22
59. Walle T, Walle UK. Stereoselective sulphate conjugation of racemic terbutaline by human liver cytosol. Br J Clin Pharmacol 1990; 30: 127-33
60. Walle T, Walle UK. Stereoselective sulphate conjugation of 4-hydroxypropranolol and terbutaline by the human liver phenolsulfotransferases. Drug Metab Dispos 1992; 20: 333-6
61. Zhang M, Fawcett JP, Kennedy JM, et al. Stereoselective glucuronidation of formoterol by human liver microsomes. Br J Clin Pharmacol 2000; 49: 152-7
62. Butter JJ, van den Berg BTJ, Portier EJG, et al. Determination by HPLC with electrochemical detection of formoterol RR and SS enantiomers in urine. J Liquid Chromatogr Rel Tech 1996; 19: 993-1005
63. Zhang M, Fawcett JP, Shaw JP. Rapid chiral high-performance liquid chromatographic assay for salmeterol and alpha-hydroxysalmeterol: application to in vitro metabolism studies. J Chromatogr B Biomed Sci Appl 1999; 729: 225-30
64. Boulton DW, Fawcett JP. Determination of salbutamol enantiomers in human plasma and urine by chiral high-performance liquid chromatography. J Chromatogr B Biomed Appl 1995; 672: 103-9
65. Boulton DW, Fawcett JP. Enantioselective disposition of salbutamol in man following oral and intravenous administration. Br J Clin Pharmacol 1996; 41: 35-40
66. Zhang M, Fawcett JP, Shaw JP. Stereoselective urinary excretion of formoterol and its glucuronide conjugate in human. Br J Clin Pharmacol. In press
67. Landoni MF, Soraci A. Pharmacology of chiral compounds: 2-arylpropionic acid derivatives. Curr Drug Metab 2001; 2: 37-51
68. Solomons TWG. Organic chemistry. 5th ed. New York: John Wiley and Sons Inc., 1992: 231-2
69. Fawcett JP, Taylor DR. Beta2-agonist enantiomers: is there a glitch with the chiral switch? Eur Respir J 1999; 13: 1223-4